Clin Transl Sci May 2023 PMID 36824030

Clinical differences in sirolimus treatment with low target levels between children and adults with vascular malformations - A nationwide trial.

Veroniek E M Harbers, Lilly G J M Zwerink, Gerard A Rongen, Willemijn M Klein, Carine J M van der Vleuten, Ingrid M P van Rijnsoever, Lynda Gerdsen-Drury, Uta E Flucke, Bas H Verhoeven, Peter C J de Laat, Chantal M A M van der Horst, Leo J Schultze Kool, D Maroeska W M Te Loo

Full text PDF Download social card

Mentions

Peak: 4 in Mar 2025

across 2 sources since Sep 2023

Extended reach

1,646

potential audience

Total likes

Video views

Mentions per month

Sep 2023 – Mar 2025

Where it's discussed

X / Twitter4 posts
YouTube1 videos

AI synopsis

What people are saying

The discussions mainly focus on acknowledging the article’s recognition as a top-cited publication, using phrases like 'Good news' and 'received enough citations,' which demonstrates a tone of academic achievement and prestige. The words and tone convey respect and acknowledgment of the publication’s significance without detailed analysis, indicating moderate engagement and interest.

AgreementNeither agree nor disagree

Both posts express positive recognition, but neither explicitly supports or questions the study’s findings, leading to a neutral agreement score.

InterestModerate interest

The posts show some interest by highlighting the article's citation success and impact, but the brief nature indicates limited personal engagement.

EngagementNeutral engagement

The discussions are mainly announcements or endorsements, not in-depth analysis or critique, reflecting low-to-moderate engagement levels.

ImpactModerate impact

The emphasis on the article being a top-cited publication suggests it has influence within academic circles, indicating a noteworthy impact.

Abstract in brief

The study found that low target levels of sirolimus (4-10 ng/mL) are effective in treating children and adults with vascular malformations, with most patients experiencing symptom improvement, though symptoms often recur after stopping treatment.
Adults tend to experience more pain and higher rates of side effects than children, but both groups respond similarly to the medication, with children responding faster and showing higher response rates.
The results suggest that early initiation of sirolimus in younger patients could be beneficial, and prolonged or lifelong treatment may be necessary due to symptom recurrence upon stopping the medication.

Read the full abstract

All mentions

Sirolimus Treatment for Vascular Malformations: Pediatric and Adult Insights

Low target levels of sirolimus effectively treat vascular malformations, improving symptoms in both children and adults. Adults experience more pain and side effects, but children respond faster. Long-term treatment may…

Medicine RTCL TV · Sep 4, 2023 6 views

GoPI3Ks (Genetic Overgrowth PI3K Support)

@GoPI3Ks · X

This is from 2023 but may still be an interesting read for some: https://t.co/xHE54oB13p https://t.co/kKRq7WtVqj

Mar 28, 2025 · 568 followers View post →

V. Harbers

@VHarbers1 · X

RT @HecovanNijmegen: Good news! Our article received enough citations to be a Top Cited Article. Read it here https://t.co/M2kLElo8TC #Top…

Mar 21, 2025 · 2 shares · 14 followers View post →

GoPI3Ks (Genetic Overgrowth PI3K Support)

@GoPI3Ks · X

RT @HecovanNijmegen: Good news! Our article received enough citations to be a Top Cited Article. Read it here https://t.co/M2kLElo8TC #Top…

Mar 20, 2025 · 2 shares · 568 followers View post →

C. van der Vleuten

@HecovanNijmegen · X

Good news! Our article received enough citations to be a Top Cited Article. Read it here https://t.co/M2kLElo8TC #TopCitedArticle @wileyinresearch

Mar 20, 2025 · 4 likes · 2 shares · 478 followers View post →